Paschalis Vergidis
YOU?
Author Swipe
View article: Candida glabrata Prosthetic Joint Infection Managed with Ibrexafungerp
Candida glabrata Prosthetic Joint Infection Managed with Ibrexafungerp Open
We report a case of a triazole and echinocandin-resistant C. glabrata right shoulder prosthetic joint infection in a 60-year-old woman. The patient underwent surgery and received the novel triterpenoid antifungal agent ibrexafungerp. She i…
View article: Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR
Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR Open
Infection is increasingly recognized as a significant cause of morbidity and mortality in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) receiving CD19 chimeric antigen receptor (CAR) T-cell therapy. The current study…
View article: Performance of BIOFIRE FILMARRAY pneumonia panel in suspected pneumonia: insights from a real-world study
Performance of BIOFIRE FILMARRAY pneumonia panel in suspected pneumonia: insights from a real-world study Open
Pneumonia may be caused by a diverse group of microorganisms; however, a microbiologic diagnosis is not universally made. Molecular tests such as the BIOFIRE FILMARRAY Pneumonia Panel (BF-PP) offer the possibility of rapid identification o…
View article: Redo bilateral lung transplantation in a previous heart-lung transplant recipient for invasive pulmonary scedosporiosis
Redo bilateral lung transplantation in a previous heart-lung transplant recipient for invasive pulmonary scedosporiosis Open
View article: A Novel Giant Magnetoresistance–Enabled Multiplex Polymerase Chain Reaction Assay for the Diagnosis of Invasive Fungal Infection
A Novel Giant Magnetoresistance–Enabled Multiplex Polymerase Chain Reaction Assay for the Diagnosis of Invasive Fungal Infection Open
Background Despite advances in clinical microbiology, the diagnosis of invasive fungal infections remains challenging. Giant magnetoresistance (GMR) is a novel technology that enables the detection of trace amounts of cell-free DNA (cfDNA)…
View article: P-1043. Risk Factors for Breakthrough Invasive Mold Infections in Patients with Hematologic Malignancies
P-1043. Risk Factors for Breakthrough Invasive Mold Infections in Patients with Hematologic Malignancies Open
Background Invasive mold infections (IMI) lead to significant morbidity and mortality in patients with hematologic malignancies. We provide patients deemed at higher risk mold active prophylaxis but still observe breakthrough IMIs. The pur…
View article: P-1713. Impact of an Evidence-Based Order Panel on Antimicrobial Prescribing in Ambulatory Patients with Complicated and Uncomplicated Cystitis
P-1713. Impact of an Evidence-Based Order Panel on Antimicrobial Prescribing in Ambulatory Patients with Complicated and Uncomplicated Cystitis Open
Background Optimizing antimicrobial prescribing for urinary tract infections (UTI) represents an area of opportunity for ambulatory antimicrobial stewardship programs. A pre-populated, ambulatory antibiotic order panel for UTI was implemen…
View article: Impact of an evidence-based order panel on antibiotic prescribing in ambulatory patients with cystitis
Impact of an evidence-based order panel on antibiotic prescribing in ambulatory patients with cystitis Open
Background: Optimizing antibiotic prescribing for urinary tract infections (UTI) represents an opportunity for ambulatory antibiotic stewardship programs (ASPs). A pre-populated order panel for UTI was implemented in the Mayo Clinic Enterp…
View article: Rapid multiplex PCR panel for pneumonia in hospitalised patients with suspected pneumonia in the USA: a single-centre, open-label, pragmatic, randomised controlled trial
Rapid multiplex PCR panel for pneumonia in hospitalised patients with suspected pneumonia in the USA: a single-centre, open-label, pragmatic, randomised controlled trial Open
bioMérieux.
View article: Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management
Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management Open
View article: Reply to Kidd et al., “Inconsistencies within the proposed framework for stabilizing fungal nomenclature risk further confusion”
Reply to Kidd et al., “Inconsistencies within the proposed framework for stabilizing fungal nomenclature risk further confusion” Open
International audience
View article: Serial Bronchoalveolar Lavage Fluid <i>Aspergillus</i> Galactomannan and Treatment Response in Invasive Pulmonary Aspergillosis
Serial Bronchoalveolar Lavage Fluid <i>Aspergillus</i> Galactomannan and Treatment Response in Invasive Pulmonary Aspergillosis Open
We studied patients diagnosed with aspergillosis based on positive bronchoalveolar lavage (BAL) Aspergillus galactomannan (GM) who had follow-up BAL sampling within 180 days. GM trend and clinical outcome were concordant in only 60% (30/50…
View article: Serial Evaluation of Preimmunization Antibody Titers in Lymphoma Patients Receiving Chimeric Antigen Receptor T Cell Therapy
Serial Evaluation of Preimmunization Antibody Titers in Lymphoma Patients Receiving Chimeric Antigen Receptor T Cell Therapy Open
Antibody titers and the potential need for immunization have not been formally studied in recipients of chimeric antigen receptor T cell therapy (CAR-T). Prior studies have shown that CD19-targeted CAR-T can induce persistent B cell aplasi…
View article: COVID-19 outcome is not affected by anti-CD20 or high-titer convalescent plasma in immunosuppressed patients
COVID-19 outcome is not affected by anti-CD20 or high-titer convalescent plasma in immunosuppressed patients Open
View article: 2952. Impacts of an evidence-based, pre-populated order panel on antimicrobial prescribing trends in ambulatory patients with community-acquired pneumonia
2952. Impacts of an evidence-based, pre-populated order panel on antimicrobial prescribing trends in ambulatory patients with community-acquired pneumonia Open
Background Optimizing antimicrobial regimens for outpatients with community-acquired pneumonia (CAP) represents an area of opportunity for ambulatory antimicrobial stewardship programs. A pre-populated, antibiotic order panel for outpatien…
View article: 830. Risk factors for late Pneumocystis jirovecii pneumonia in kidney transplant recipients: A Case-Control Study of United States Renal Data System Data
830. Risk factors for late Pneumocystis jirovecii pneumonia in kidney transplant recipients: A Case-Control Study of United States Renal Data System Data Open
Background Organ transplant recipients are at increased risk of potentially life-threatening opportunistic infections, including Pneumocystis jirovecii pneumonia (PJP). Given the use of effective prophylaxis, PJP has become less common, es…
View article: Evaluation of Multisite Programmatic Bundle to Reduce Unnecessary Antibiotic Prescribing for Respiratory Infections: A Retrospective Cohort Study
Evaluation of Multisite Programmatic Bundle to Reduce Unnecessary Antibiotic Prescribing for Respiratory Infections: A Retrospective Cohort Study Open
Background The aim of this study was to evaluate the frequency of unnecessary antibiotic prescribing for Tier 3 upper respiratory infection (URI) syndromes across the Mayo Clinic Enterprise before and after a multifaceted antimicrobial ste…
View article: A conceptual framework for nomenclatural stability and validity of medically important fungi: a proposed global consensus guideline for fungal name changes supported by ABP, ASM, CLSI, ECMM, ESCMID-EFISG, EUCAST-AFST, FDLC, IDSA, ISHAM, MMSA, and MSGERC
A conceptual framework for nomenclatural stability and validity of medically important fungi: a proposed global consensus guideline for fungal name changes supported by ABP, ASM, CLSI, ECMM, ESCMID-EFISG, EUCAST-AFST, FDLC, IDSA, ISHAM, MMSA, and MSGERC Open
The rapid pace of name changes of medically important fungi is creating challenges for clinical laboratories and clinicians involved in patient care. We describe two sources of name change which have different drivers, at the species versu…
View article: Description of Cryptococcosis Following SARS-CoV-2 Infection: A Disease Survey Through the Mycosis Study Group Education and Research Consortium (MSG-19)
Description of Cryptococcosis Following SARS-CoV-2 Infection: A Disease Survey Through the Mycosis Study Group Education and Research Consortium (MSG-19) Open
Background Invasive fungal infections have been described throughout the COVID-19 pandemic. Cryptococcal disease after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been reported in several isolated case r…
View article: The Role of Novel Antifungals in the Management of Candidiasis: A Clinical Perspective
The Role of Novel Antifungals in the Management of Candidiasis: A Clinical Perspective Open
Mucosal and invasive candidiasis can be challenging to treat in the setting of drug intolerance, antifungal resistance, drug–drug interactions, or host immune status. Antifungals with novel mechanisms of action and distinct pharmacokinetic…
View article: Antifungal Stewardship Interventions in Patients with Hematologic Malignancies
Antifungal Stewardship Interventions in Patients with Hematologic Malignancies Open
View article: Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma
Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma Open
View article: Real‐world experience of tixagevimab‐cilgavimab pre‐exposure prophylaxis in orthotopic heart transplant recipients
Real‐world experience of tixagevimab‐cilgavimab pre‐exposure prophylaxis in orthotopic heart transplant recipients Open
Background Pre‐exposure prophylaxis with tixagevimab‐cilgavimab (tix‐cil) may be associated with cardiovascular adverse events. Also, in vitro studies have reported a reduced activity of tix‐cil against emerging SARS‐CoV‐2 Omicron subvaria…
View article: The Brief Case: the Cryptic <i>Cryptococcus</i>
The Brief Case: the Cryptic <i>Cryptococcus</i> Open
A 64-year-old male with a history of nonalcoholic steatohepatitis, alpha-1-antitrypsin deficiency, and an orthotopic liver transplant completed 5 months prior, presented to the hospital with a 1-day history of fever and fatigue. The patien…
View article: Transplantid.net: A Pilot Crowdsourced, Living, Online Library of Resources for the Teaching and Practice of Transplant Infectious Diseases
Transplantid.net: A Pilot Crowdsourced, Living, Online Library of Resources for the Teaching and Practice of Transplant Infectious Diseases Open
The field of transplant infectious diseases is rapidly evolving, presenting a challenge for clinical practice and trainee education. Here we describe the construction of transplantid.net, a free online library, crowdsourced and continuousl…
View article: Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis
Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis Open
View article: 755. Predictors of Mortality in Invasive Mold Infections Among Patients with Hematologic Malignancies and Hematopoietic Stem Cell Transplant Recipients
755. Predictors of Mortality in Invasive Mold Infections Among Patients with Hematologic Malignancies and Hematopoietic Stem Cell Transplant Recipients Open
Background Invasive Mold Infections (IMI) cause significant morbidity and mortality, particularly in patients with hematologic malignancies (HM) and hematopoietic stem cell transplant (HSCT) recipients. Although the risk has significantly …
View article: 475. Does Metabolite Matter? Defining Target Itraconazole and Hydroxy-itraconazole Serum Levels for Blastomycosis
475. Does Metabolite Matter? Defining Target Itraconazole and Hydroxy-itraconazole Serum Levels for Blastomycosis Open
Background Itraconazole is first-line treatment for mild-moderate blastomycosis and consolidation of moderate-severe disease. Itraconazole is metabolized to 3 metabolites, including an active metabolite hydroxy-itraconazole. The sum of itr…
View article: 1752. Impact of a multifaceted, outpatient antimicrobial stewardship intervention bundle on unnecessary antimicrobial prescribing in upper respiratory tract infections (URI)
1752. Impact of a multifaceted, outpatient antimicrobial stewardship intervention bundle on unnecessary antimicrobial prescribing in upper respiratory tract infections (URI) Open
Background URIs are the most common indication for outpatient antibiotic prescribing. Given high rates of unnecessary prescribing, these indications have been identified as a high-priority target for outpatient antimicrobial stewardship pr…
View article: 751. Decoding a Decade: Temporal Trends of MIC Distribution of Antifungals Against <i>Cryptococcus</i> species From a Reference Laboratory
751. Decoding a Decade: Temporal Trends of MIC Distribution of Antifungals Against <i>Cryptococcus</i> species From a Reference Laboratory Open
Background There are not established clinical breakpoints (CBP) for antifungals against Cryptococcus species; However, the analysis of their MICs using epidemiological cut-off values (ECVs) can help to distinguish wild-type (WT) isolates f…